You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company reported $38.4 million in total revenues for the quarter and said testing services revenues rose 46 percent year over year.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.
CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.
The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.
The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
Time magazine looks into how liquid biopsies are changing cancer care.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.